Emb
Latest news and updates related to emb
About Emb coverage
The Emb news hub on Global Investing News tracks 238 recent headlines that matter to investors, policy watchers, and market strategists. Use this page to monitor how Emb developments affect earnings expectations, sector rotation, supply chains, regulation, and cross-asset volatility. Stories are grouped by source type — market data, company announcements, regulatory filings, and expert analysis — so you can scan the signal quickly without wading through duplicate wire copy. When a headline links to a full article, you will find expanded context, key facts, and prediction-market angles where available. Bookmark this hub if you follow Emb across quarters; new items are added as our crawl pipeline ingests fresh sources throughout the trading day.
Explore related topics
Latest Emb headlines
Market Data
(5)U.S. economy adds just 29,000 jobs in September
U.S. economy adds just 29,000 jobs in September
'AI or bust:' Tech trade powered stocks through volatile September
'AI or bust:' Tech trade powered stocks through volatile September
S&P 500, Dow, Nasdaq End Lower As Surging Oil Raises Odds For A September Rate Hike — ORCL, ADBE, M, NVDA, UBER In Focus
S&P 500, Dow, Nasdaq End Lower As Surging Oil Raises Odds For A September Rate Hike — ORCL, ADBE, M, NVDA, UBER In Focus
There Are Only a Handful of S&P 500 Stocks That Yield Over 5%. Here's My Top Pick to Buy in September.
There Are Only a Handful of S&P 500 Stocks That Yield Over 5%. Here's My Top Pick to Buy in September.
Traders Bet Warsh's Fed Will Hike Rates by December
Traders Bet Warsh's Fed Will Hike Rates by December
Expert Analysis
(2)CRWV Faces High Stakes November 10th Earnings Print Amid Rising Infrastructure Spend
Coastline Renewable & Water (CRWV) is scheduled to release its fiscal quarter results on November 10, 2026, during active trading hours. Wall Street analysts have set a challenging bar for the utility and infrastructure giant, with a consensus Revenue estimate of $3.62B and a projected Earnings Per Share (EPS) of -$1.1831. This negative bottom-line forecast reflects the company’s ongoing aggressive capital expenditure cycle and elevated debt-servicing costs associated with its multi-year grid modernization initiatives. Investors will be scrutinizing the report for signs of operational efficiency that could offset the projected net loss. Key metrics to watch include the company’s operating margins and its updates on regulatory rate-case approvals, which serve as the primary catalyst for revenue growth in the coming fiscal year. Historically, CRWV has exhibited high volatility following earnings announcements, often swinging based on management’s forward guidance rather than the immediate bottom-line result. In the previous four quarters, CRWV has beaten revenue estimates twice but struggled to contain cost overruns, leading to mixed market reactions. Analyst consensus remains cautiously positioned. While the $3.62B revenue target represents a steady year-over-year increase, the projected loss per share suggests that the path to profitability remains hindered by inflationary pressures on raw materials. If CRWV manages to report a narrower-than-expected loss or provides a bullish outlook on contract backlogs, the stock could see a significant relief rally. Conversely, any further slippage in project timelines or an increase in the projected net loss could lead to a breach of technical support levels. Market participants should prepare for heightened intraday volatility as the figures hit the tape during the trading session.
Amgen Q3 Preview: Obesity Pipeline and Rare Disease Portfolio in Focus Ahead of November 3 Print
Amgen (AMGN) is scheduled to report its third-quarter 2026 financial results on November 3, after the market close. The biotechnology giant faces a critical test as investors look for sustained momentum following its integration of Horizon Therapeutics and progress in its high-stakes metabolic pipeline. Wall Street consensus currently estimates Earnings Per Share (EPS) of $5.91 on revenue of $10.27 billion. The quarter’s performance will likely hinge on the commercial trajectory of Tepezza and Krystexxa, alongside the volume growth of its core oncology and inflammation franchises. Key metrics for this release include updates on MariTide, Amgen’s injectable GLP-1/GIP receptor antagonist. With the obesity market reaching a fever pitch, any granular data regarding Phase 3 progress or manufacturing capacity could trigger significant volatility. Historically, Amgen has demonstrated a robust ability to manage operating margins, though increased R&D spending for its late-stage pipeline remains a point of scrutiny. The company has a consistent track record of meeting or slightly exceeding EPS estimates, having beaten consensus in three of the last four quarters. Potential market impact will be driven by the 2026 full-year guidance narrow. If Amgen signals that its biosimilar defense strategy is holding firm against legislative pricing pressures and competition, the stock could see a valuation re-rating. Conversely, any softness in the rare disease segment or delays in clinical timelines could weigh on the share price. Analysts will also be listening for updates on the capital allocation strategy, specifically regarding debt reduction following recent large-scale acquisitions.
Get alerts for this topic
Subscribe to receive updates about "Emb"